A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Urologic Oncology: Seminars and Original Investigations.
Times cited: 27
Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research.
Clinical Genitourinary Cancer.
Times cited: 17
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Clinical Cancer Research.
Times cited: 73
- Innovations and Challenges in Prostate Cancer: Summary Statement for the 6th Cambridge Conference. Journal of Urology. 2007 Article GET IT